The Discovery of Captopril

  title={The Discovery of Captopril},
  author={Charles G. Smith and John Robert Vane},
  journal={The FASEB Journal},
Over the past few years, and particularly recently, there has been a goodly amount of discussion in the press about the discovery and development of highly successful drugs by the pharmaceutical industry, in which extensive data generated by government-sponsored research is claimed to have played a significant role in the industry’s success. Detailed analysis of these claims (1) has concluded that the concept of major monetary input into such drugs by the government is not justified. Indeed… 

Introduction to drug discovery

  • S. Ashenden
  • Biology
    The Era of Artificial Intelligence, Machine Learning, and Data Science in the Pharmaceutical Industry
  • 2021

Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.

  • Matthias Adam
  • Biology
    Studies in history and philosophy of biological and biomedical sciences
  • 2005

Some useful pharmazooticals, now and in the future

Animals remain an important source of drugs in the search for new medicinal compounds. Drugs from animal sources include insulin, pituitary hormones, vitamins, and antibiotics and biological agents,

Toxins and drug discovery.

  • A. Harvey
  • Biology
    Toxicon : official journal of the International Society on Toxinology
  • 2014

Finding new drug targets in the 21st century.

The role of natural products in modern drug discovery.

  • J. Calixto
  • Environmental Science, Biology
    Anais da Academia Brasileira de Ciencias
  • 2019
The most challenging ones are i) the lack of specific regulations to allow researchers and companies to access biodiversity for the purposes of scientific and technological innovation; and ii) the absence of a long-term government program to support research and innovation in this field.

A new model for utilising chemical diversity from natural sources

Through a judicious combination of new technologies and compelling business model, at least one Singapore‐based company is offering cost‐effective solutions for accessing the unique chemical diversity found in Nature.

Targeting eukaryotic proteases for natural products-based drug development.

This review will discuss some of the current and emerging drug targets and their involvement in various disease processes, highlighting selected success stories behind several FDA-approved protease inhibitors that have natural products scaffolds as well as recent selected pharmacologically well-characterized inhibitors derived from marine or terrestrial sources.



Public and private sector contributions to the discovery and development of "impact" drugs.

An assessment of the relationship between the private and public sectors in drug discovery and development of 21 "impact" drugs found that any attempt to measure the relative contribution of the public and private sectors to the research and development (R&D) of therapeutically important drugs is flawed.